Our study investigated whether anti-Tim-3 and anti-PD-1 antibodies could enhance the tumor-specific immune response of DC-CIK cells and produce a more substantial tumor-killing effect by blocking the cell surface Tim-3 and PD-1 signaling pathways. This evidence concerns the gene HAVCR2 and neoplasm.